Edition:
United Kingdom

Biomerieux SA (BIOX.PA)

BIOX.PA on Paris Stock Exchange

72.30EUR
4:35pm BST
Change (% chg)

€0.45 (+0.63%)
Prev Close
€71.85
Open
€71.80
Day's High
€72.35
Day's Low
€71.45
Volume
94,355
Avg. Vol
106,273
52-wk High
€82.60
52-wk Low
€53.10

Latest Key Developments (Source: Significant Developments)

BioMerieux Increases Its Holding In Hybiome To 67%
Thursday, 6 Jun 2019 

June 6 (Reuters) - BIOMERIEUX SA ::BIOMÉRIEUX INCREASES ITS HOLDING IN HYBIOME FROM 54% TO 67%.AN ADDITIONAL 13% STAKE HAS BEEN ACQUIRED FOR ABOUT 20 MILLION EUROS.ADDITIONAL 13% STAKE HAS BEEN ACQUIRED FOR ABOUT 20 MILLION EUROS.FOLLOWING THIS TRANSACTION, BIOMÉRIEUX NOW HOLDS 67% OF SHARES OF HYBIOME.  Full Article

Baxter And Biomérieux Collaborate On Identification And Treatment Of Acute Kidney Injury
Tuesday, 19 Mar 2019 

March 19 (Reuters) - BAXTER INTERNATIONAL INC ::BAXTER AND BIOMÉRIEUX ANNOUNCE COLLABORATION TO IMPROVE IDENTIFICATION AND TREATMENT OF ACUTE KIDNEY INJURY.  Full Article

Biomerieux FY Operating Income Up At 344 Million Euros
Wednesday, 27 Feb 2019 

Feb 27 (Reuters) - BIOMERIEUX SA ::FY SALES EUR 2.42 BILLION VERSUS EUR 2.29 BILLION YEAR AGO.FY OPERATING INCOME EUR 344 MILLION VERSUS EUR 315 MILLION YEAR AGO.FY NET INCOME OF CONSOLIDATED COMPANIES EUR 256 MILLION VERSUS EUR 238 MILLION YEAR AGO.FOR 2019: ORGANIC GROWTH IN SALES OF BETWEEN 7.0% AND 8.5%, AT CONSTANT EXCHANGE RATES AND SCOPE OF CONSOLIDATION.FOR 2019: CONTRIBUTIVE OPERATING INCOME BEFORE NON-RECURRING ITEMS OF BETWEEN EUR 385 MILLION AND EUR 400 MILLION, AT CURRENT EXCHANGE RATES.WILL RECOMMEND THAT SHAREHOLDERS AT THE ANNUAL GENERAL MEETING ON MAY 23, 2019 APPROVE A DIVIDEND OF €0.35 PER SHARE FOR FY.BIOMÉRIEUX EXPECTS SALES GROWTH TO BE WEAKER IN FIRST-QUARTER 2019 THAN IN THE OTHER QUARTERS.  Full Article

Biomérieux Acquires A Majority Stake In Hybiome
Friday, 9 Nov 2018 

Nov 9 (Reuters) - BIOMERIEUX SA ::BIOMÉRIEUX ACQUIRES A MAJORITY STAKE IN HYBIOME AND STRENGTHENS ITS PRESENCE BOTH IN CHINA AND IN THE IMMUNOASSAY MARKET.ACQUISITION OF 54% OF SHARES OF HYBIOME RELIES ON A EUR 165 MILLION VALUATION, ON TOP OF WHICH ADDITIONAL EXPENSES OF 25 MILLION EUROS WERE INCURRED AS CONSIDERATION FOR ADDITIONAL ASSETS.  Full Article

Biomerieux 9-Month Sales Up At 1.75 Billion Euros
Thursday, 18 Oct 2018 

Oct 18 (Reuters) - BIOMERIEUX SA ::BIOMÉRIEUX – BUSINESS REVIEW FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2018.9M EUR 1,749 MILLION IN SALES UP 4.5% AS REPORTED.ON TRACK TO ACHIEVING ITS FINANCIAL OBJECTIVES FOR YEAR.  Full Article

Biomerieux Launches Endozyme II Go
Thursday, 31 May 2018 

May 31 (Reuters) - BIOMERIEUX SA ::BIOMÉRIEUX LAUNCHES ENDOZYME® II GO, A TEST FOR THE DETECTION OF ENDOTOXINS IN PHARMACEUTICAL MICROBIOLOGY CONTROL.  Full Article

Biomerieux FY Sales Up At 2.29 Billion Euros
Wednesday, 28 Feb 2018 

Feb 28 (Reuters) - BIOMERIEUX SA ::FY SALES EUR 2.29 BILLION VERSUS EUR 2.10 BILLION YEAR AGO.FY OPERATING INCOME EUR 315 MILLION VERSUS EUR 282 MILLION YEAR AGO.FY RESULT EUR 238 MILLION VERSUS EUR 179 MILLION YEAR AGO.FOR 2018 EXPECTS ORGANIC SALES GROWTH OF BETWEEN 8 AND 9 PERCENT, AT CONSTANT EXCHANGE RATES AND PERIMETER.FOR 2018 EXPECTS CONTRIBUTING CURRENT OPERATING INCOME OF BETWEEN € 325 AND € 345 MILLION.TO PROPOSE A DIVIDEND OF EUR 0.34 PER SHARE.  Full Article

Biomerieux Q3 sales up at ‍​1.67 billion euros
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - BIOMERIEUX SA ::Q3 SALES EUR ‍​1.67 BILLION VERSUS EUR 1.51 BILLION YEAR AGO.  Full Article

Biomerieux H1 operating income rises to 163 million euros
Wednesday, 30 Aug 2017 

Aug 30 (Reuters) - BIOMERIEUX SA ::IS NOW TARGETING ORGANIC SALES GROWTH FOR FULL YEAR OF BETWEEN 9 PCT AND 10 PCT.EUR 1,134 MILLION IN SALES ‍​IN H1, UP 13.3 PCT AS REPORTED.IS NOW AIMING TO DELIVER FULL-YEAR CONTRIBUTIVE OPERATING INCOME BEFORE NON-RECURRING ITEMS OF BETWEEN EUR 330 MILLION AND EUR 345 MILLION.IN H1 18 PCT INCREASE IN NET INCOME TO EUR 101 MILLION.2017 FINANCIAL TARGETS REVISED: ORGANIC GROWTH IN SALES OF BETWEEN 9 PCT AND 10 PCT ‍​.H1 OPERATING INCOME EUR 163 MILLION VERSUS EUR 146 MILLION YEAR AGO.  Full Article

Biomérieux receives FDA clearance for expanded pathogen identification capability on VITEK® MS
Monday, 31 Jul 2017 

July 31 (Reuters) - BIOMERIEUX SA : :BIOMÉRIEUX RECEIVES FDA CLEARANCE FOR EXPANDED PATHOGEN IDENTIFICATION CAPABILITY ON VITEK® MS.  Full Article